Two of the most common MSC sources, compared on the factors that actually differ between them.
Bone marrow MSCs are obtained via marrow aspiration, typically from the iliac crest, under local or general anesthesia — an invasive procedure performed on the person providing the tissue. Umbilical cord tissue is recovered from the cord and placenta after a healthy birth, from a consenting donor, using tissue that is otherwise discarded as medical waste. This makes cord tissue collection non-invasive to the donor.
MSC proliferative capacity generally declines with donor age — a well-documented effect across multiple tissue sources. Because umbilical cord tissue is collected at birth, it avoids this age-related decline entirely, and cord-derived MSCs are generally reported in the literature to proliferate faster in culture than MSCs from adult bone marrow, particularly from older donors.
Bone marrow, by contrast, is sourced from donors across the age spectrum, and quality/yield can vary considerably depending on donor health and age at the time of collection.
Bone marrow MSCs have the longest clinical research history of any MSC source, with decades of published trials. Umbilical cord tissue is a comparatively newer source in widespread clinical use but has grown rapidly in both research volume and commercial use over the past decade.
Both source types, when processed into an HCT/P (human cell, tissue, or cellular/tissue-based product), are regulated under 21 CFR Part 1271 in the United States, and neither source type confers FDA approval by itself — approval status depends on the specific product, its manipulation, and its intended use.
This page is educational reference material for licensed healthcare providers and does not constitute medical, legal, or regulatory advice. HCT/P products are not FDA-approved.